The Latest Breaking News from FDA

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

The federal government has legalized cannabidiol (CBD). The FDA also has approved one cannabis-derived prescription drug, Epidiolex, for three rare seizure conditions.

Here's a roundup of top developments in the biotech space over the last 24 hours:

The Biden administration may scrap plans to expand eligibility for second boosters to younger adults. Instead, it's trying to speed up the next generation of boosters targeting the omicron variant.

Maggie Carmichael wasn’t developing like other kids. As a toddler, she wasn’t walking and had a limited vocabulary for her age.

By Peter Loeb, CEO of Lionrock

The FDA should not stand in the way of parents doing what’s best for their children.

An NPR investigation found stalled confirmatory trials and lax enforcement are plaguing the FDA's accelerated approval of drugs for urgent medical needs.

AstraZeneca announced looming approval for two drugs in Europe and an FDA review for a third med, leading AZN stock to inch higher Monday.

Key Takeaways: RLX has received a new manufacturing license as required under a new regulation announced earlier this year The license permits the company to produce rechargeable vaping devices at levels about 30% lower than its sales last year By Doug Young

Here's a roundup of top developments in the biotech space over the last 24 hours: